Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit

Background The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and declining efficacy. One potential new target for Chagas' disease chemotherapy is sterol 14α-demethylase (CYP51), a cytochrome P450 enzyme involved in biosynthesis of membrane sterols. Methodology/Principal Finding In a screening effort targeting Mycobacterium tuberculosis CYP51 (CYP51Mt), we previously identified the N-[4-pyridyl]-formamide moiety as a building block capable of delivering a variety of chemotypes into the CYP51 active site. In that work, the binding modes of several second generation compounds carrying this scaffold were determined by high-resolution co-crystal structures with CYP51Mt. Subsequent assays against the CYP51 orthologue in T. cruzi, CYP51Tc, demonstrated that two of the compounds tested in the earlier effort bound tightly to this enzyme. Both were tested in vitro for inhibitory effects against T. cruzi and the related protozoan parasite Trypanosoma brucei, the causative agent of African sleeping sickness. One of the compounds had potent, selective anti–T. cruzi activity in infected mouse macrophages. Cure of treated host cells was confirmed by prolonged incubation in the absence of the inhibiting compound. Discrimination between T. cruzi and T. brucei CYP51 by the inhibitor was largely based on the variability (phenylalanine versus isoleucine) of a single residue at a critical position in the active site. Conclusions/Significance CYP51Mt-based crystal structure analysis revealed that the functional groups of the two tightly bound compounds are likely to occupy different spaces in the CYP51 active site, suggesting the possibility of combining the beneficial features of both inhibitors in a third generation of compounds to achieve more potent and selective inhibition of CYP51Tc.

[1]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[2]  M. Waterman,et al.  CYP51 from Trypanosoma cruzi , 2006, Journal of Biological Chemistry.

[3]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[4]  M. Waterman,et al.  CYP51 from Trypanosoma brucei is obtusifoliol-specific. , 2004, Biochemistry.

[5]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[6]  D. Rice,et al.  Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. , 2003, Molecular and biochemical parasitology.

[7]  S. Furlong Sterols of parasitic protozoa and helminths. , 1989, Experimental parasitology.

[8]  J. McKerrow,et al.  Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.

[9]  T. Richardson,et al.  Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. , 1997, Archives of biochemistry and biophysics.

[10]  H. Barnes,et al.  Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[12]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[13]  J. Dvorak,et al.  Trypanosoma cruzi: quantification and analysis of the infectivity of cloned stocks. , 1984, The Journal of protozoology.

[14]  N. Georgopapadakou,et al.  Antifungals: mechanism of action and resistance, established and novel drugs. , 1998, Current opinion in microbiology.

[15]  J. McKerrow,et al.  A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection , 2007, Antimicrobial Agents and Chemotherapy.

[16]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  N. Galanti,et al.  Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. , 2007, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[18]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[19]  S. Kaufmann,et al.  X-ray Structure of 4,4′-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14α-Demethylase (CYP51)*♦ , 2008, Journal of Biological Chemistry.

[20]  R. Docampo,et al.  Sterol biosynthesis inhibitors: potential chemotherapeutics against Chagas disease. , 1997, Parasitology today.

[21]  E. Dalmasso,et al.  Estriol Bound and Ligand-free Structures of Sterol 14α-Demethylase , 2004 .

[22]  M. Waterman,et al.  Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography , 2007, Antimicrobial Agents and Chemotherapy.

[23]  J. Jannin,et al.  The future of Chagas disease control. , 2006, Trends in parasitology.

[24]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[25]  J. Lynch,et al.  Steroids and Squalene in Methylococcus capsulatus grown on Methane , 1971, Nature.

[26]  T. Poulos,et al.  Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. , 2001, Journal of inorganic biochemistry.

[27]  S. Boyle,et al.  Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylase , 2003 .

[28]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.

[29]  C. Beard,et al.  Control of Chagas Disease. Second Report of the WHO Expert Committee. WHO Technical Report Series, No. 905. Geneva: World Health Organization, 2002. vi + 109pp. Price Sw.fr. 23/US$20.70 (in developing countries Sw.fr.16.10). ISBN 92-4-120905.4 , 2002 .

[30]  P. Wincker,et al.  Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870 , 1996, Science.

[31]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[32]  Sarman Singh,et al.  Chemotherapy of leishmaniasis: past, present and future. , 2007, Current medicinal chemistry.

[33]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[34]  S. Boyle,et al.  Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. , 2003, Molecular and biochemical parasitology.

[35]  M. Gelb,et al.  A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y. Aoyama Recent progress in the CYP51 research focusing on its unique evolutionary and functional characteristics as a diversozyme P450. , 2005, Frontiers in Bioscience.

[37]  A. Romanha,et al.  Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. , 2003, International journal of antimicrobial agents.